Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
BörsenkürzelXAIR
Name des UnternehmensBeyond Air Inc
IPO-datumMay 07, 2019
CEOLisi (Steven A)
Anzahl der mitarbeiter61
WertpapierartOrdinary Share
GeschäftsjahresendeMay 07
Addresse900 Stewart Ave
StadtGARDEN CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl11530
Telefon15166658200
Websitehttps://www.beyondair.net/
BörsenkürzelXAIR
IPO-datumMay 07, 2019
CEOLisi (Steven A)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten